Aiming to discover further potential treatment approaches, we investigated the role of MR3 expression in the CRC tumor immune microenvironment by immunohistochemical analysis for a selection of promising immunomarkers: CD8, FOXP3, IL17, TIA-1, CD16 and OX40. Here, TNFRSF4 is linked to neoplasm.